Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 8.39B P/E 202.35 EPS this Y 360.00% Ern Qtrly Grth -
Income -1.04B Forward P/E 38.78 EPS next Y 64.30% 50D Avg Chg 8.00%
Sales 4.38B PEG 1.63 EPS past 5Y -2.13% 200D Avg Chg -10.00%
Dividend N/A Price/Book 1.78 EPS next 5Y 32.41% 52W High Chg -60.00%
Recommedations 3.00 Quick Ratio 1.74 Shares Outstanding 181.46M 52W Low Chg 48.00%
Insider Own 0.59% ROA 0.04% Shares Float 180.30M Beta 1.16
Inst Own 93.25% ROE -25.39% Shares Shorted/Prior 9.51M/8.53M Price 46.54
Gross Margin 21.75% Profit Margin -23.81% Avg. Volume 4,534,559 Target Price 60.75
Oper. Margin 9.15% Earnings Date Nov 13 Volume 1,895,705 Change 0.06%
About Catalent, Inc.

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Catalent, Inc. News
CTLT Chatroom

User Image ChristaBoarts Posted - 1 day ago

$CTLT Positive clinical trial outcomes suggest a strong growth trajectory for CRDL’s stock in the healthcare market.

User Image Lennox_Michael Posted - 2 days ago

$CTLT $EXEL LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image MarkoPo Posted - 2 days ago

[ $CTLT $EXEL] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image BrendanShaffer Posted - 6 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $SRPT $CTLT

User Image Estimize Posted - 1 week ago

Wall St is expecting 0.14 EPS for $CTLT Q2 [Reporting 02/11 BMO] http://www.estimize.com/intro/ctlt?chart=historical&metric_name=eps&utm_co

User Image DonCorleone77 Posted - 2 weeks ago

$CTLT Catalent reports Q1 EPS (13c), consensus 5c Reports Q1 revenue $ $1.02B , consensus $1.06B...Q1'25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. "Our first quarter fiscal 2025 results reflect the continued momentum in our business and underscore our customers' continued confidence in Catalent. Financial highlights in the quarter included double-digit year-over-year growth in both non-COVID revenue and adjusted EBITDA, while also delivering positive free cash flow," said Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc. Commenting on Catalent's pending transaction with Novo Holdings A/S ("Novo Holdings"), which is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals, Mr. Maselli said, "We are confident in the pro-competitive nature of our transaction with Novo Holdings and continue to work cooperatively with regulators towards transaction close. As a private company under Novo Holdings' ownership, Catalent will continue to operate nearly 50 global sites and serve as a leading global, independent, full-service CDMO. Post-closing, we believe Catalent will be even better positioned to develop and expand the supply of innovative treatments and cures for patients, ensure unparalleled service for our customers, and create new jobs."

User Image swingingtech Posted - 2 weeks ago

$CTLT https://wallstreetwaves.com/strategically-purchase-catalent-at-55-to-achieve-1-5-annualized-returns-through-options/

User Image Estimize Posted - 10/28/24

Wall St is expecting 7.78% YoY revenue growth for $CTLT in Q1, down from 21.82% in Q4 [Reporting 11/05 BMO] http://www.estimize.com/intro/c

User Image LMDX Posted - 10/26/24

$CTLT Becomes ADR since too much manipulation in the USA like Nasdaq, business prefer OTC where they aren't robbing shareholders. Dilution delist reverse split Dilution RS delist shorted to hell darkpools etc.

User Image WeeklyTrader Posted - 4 weeks ago

What’s your plan if $CTLT continues to drop? RSI: 43.4% 50-day MA: $60.11 200-day MA: $56.98

User Image cb1961 Posted - 1 month ago

$CTLT anyone know why NVO would purchase CTLT? What do they have in the pipeline or are they just looking to have a foothold in USA. Just curious I do not own the stock, just thought someone in here might have some knowledge. tIA.

User Image StocktwitsNews Posted - 1 month ago

Catalent CEO Assures Continuity After Novo Holdings Buyout: Retail Investors Wait And Watch. $CTLT https://stocktwits.com/news-articles/markets/equity/catalent-ceo-asserts-he-will-continue-leading-firm-post-acquisition-by-novo/cJ2a484Re2

User Image insiderbuyingselling Posted - 1 month ago

$CTLT new insider selling: 320 shares. http://insiderbuyingselling.com/?t=CTLT

User Image bhaviknair Posted - 1 month ago

$CTLT, $NVO Catalent CEO Assures Continuity After Novo Holdings Buyout: Retail Investors Wait And Watch https://stocktwits.com/news-articles/markets/equity/catalent-ceo-asserts-he-will-continue-leading-firm-post-acquisition-by-novo/cJ2a484Re2

User Image PopPortfolios Posted - 1 month ago

$CTLT oh dear.. not looking good. Might not be a bad thing as it is a bit of stinker of deal for current holders Consumer groups ask FTC to block Novo Holdings-Catalent deal https://www.reuters.com/business/healthcare-pharmaceuticals/consumer-groups-ask-ftc-block-novo-holdings-catalent-deal-2024-10-17/

User Image WeeklyTrader Posted - 1 month ago

What do you think about $CTLT’s outlook? RSI: 56.26% 50-day MA: $60.03 200-day MA: $56.51

User Image Benzinga Posted - 1 month ago

ecommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival $HAL $CTLT $LLY $UEC https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca

User Image OpenOutcrier Posted - 1 month ago

$CTLT (+0.0% pre) Catalent sells New Jersey facility to Ardena - inv https://ooc.bz/l/44650

User Image DonCorleone77 Posted - 1 month ago

$CTLT Catalent to Sell Somerset, NJ oral solids facility Catalent has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected to close in early 2025, have not been disclosed. The Somerset facility also houses Catalent's corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new location. The new location of the corporate headquarters will be announced at a later date.

User Image TalkMarkets Posted - 1 month ago

Four Stocks To Watch This Week - Tuesday, Oct. 01 $KR $INTC $CTLT $IQV https://talkmarkets.com/content/stocks--equities/four-stocks-to-watch-this-week-tuesday-oct-01?post=463767

User Image insiderbuyingselling Posted - 09/27/24

$CTLT new insider selling: 1994 shares. http://insiderbuyingselling.com/?t=CTLT

User Image JackDarwin Posted - 09/24/24

$CTLT Bullish ENgulfing Formed With good Volume. https://www.stockaio.com/US/ai/Stock/CTLT/Candlestick

User Image cubie Posted - 2 months ago

@hill13579 @SenecaAnalysis @Pepper214 $pfe $bmy $vrtx Pfizer, does not lose money lol. they make money out the wazoo. can't take non cash impairment charges write downs and say these big pharma companies lose money! so peppers list really down to just 5 or so like cubie said pus $ctlt bought out by nvo. $ttwo will make money out the wazoo too once the new Grand Theft Auto comes out. s&p not goilnna remove ttwo before that huge catalyt 🤔🙄 Anyway, the 5 or so that actually loses $$ are on chopping block to be removed to make room for the PROFITABLE ONES. dell, wday, apo top 3 guesses😏😅

User Image cubie Posted - 2 months ago

@Pepper214 @SenecaAnalysis $ctlt got bought out so that be next to go

User Image JackDarwin Posted - 08/29/24

$CTLT Nice Gap Up Formed.

User Image mark8320 Posted - 08/29/24

$CTLT when is the Novo takeover expected to close?

User Image epsguid Posted - 08/29/24

$CTLT reported earnings of $0.57, consensus was $0.44 via @eWhispers #epsbeat http://eps.sh/d/ctlt

User Image DonCorleone77 Posted - 08/29/24

$CTLT Catalent reports Q4 adjusted EPS 65c, consensus 47c Reports Q4 revenue $1.3B, consensus $1.22B. "I am pleased to report that Catalent ended our fiscal 2024 in a strong position, including growing non-COVID revenue by nearly 30% in the fourth quarter and, as we had forecasted a year ago, exiting fiscal 2024 with company-wide adjusted EBITDA margin closer to historical levels. These strong results were achieved while also delivering record fourth quarter new business wins and generating positive free cash flow in excess of $100 million in the last three months of our fiscal year," said Alessandro Maselli, president and CEO of Catalent, Inc.

User Image Stock_Titan Posted - 08/29/24

$CTLT Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results https://www.stocktitan.net/news/CTLT/catalent-inc-reports-fourth-quarter-and-fiscal-2024-oxzthzwovcmp.html

User Image slimfalyfe Posted - 08/27/24

yea .. the energy sector one uh them ones right now but fr .. there is only one company with uh earnings call for today amongst all sector etfs.. n that's in the $ctlt .. uh company in the healthcare sector ( $xlv ) .. which closed in the red on monday .. #theoptionschat💲

Analyst Ratings
Baird Neutral Sep 24, 24
William Blair Market Perform Sep 3, 24
RBC Capital Sector Perform Jul 11, 24
Barclays Equal-Weight Jun 28, 24
Stephens & Co. Equal-Weight Apr 4, 24
RBC Capital Sector Perform Feb 20, 24
RBC Capital Sector Perform Feb 6, 24
UBS Neutral Feb 6, 24
Stephens & Co. Equal-Weight Feb 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GREISCH JOHN J Executive Chair Executive Chair Aug 30 Buy 50.24 21,000 1,055,040 34,000 09/01/23
Maselli Alessandro President & CEO President & CEO Aug 23 Sell 44.83 2,071 92,843 88,004 08/25/23
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Aug 23 Sell 44.57 269 11,989 29,932 08/25/23
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Aug 23 Sell 44.5 390 17,355 24,449 08/25/23
Gennadios Aristippos Group Pres. Pharma &.. Group Pres. Pharma & Consumer Aug 23 Sell 44.49 396 17,618 96,552 08/25/23
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Aug 23 Sell 44.65 817 36,479 73,789 08/25/23
Carletti Lorenzo SVP Global Ops Ph &.. SVP Global Ops Ph & Cons Hlth Aug 23 Sell 44.71 216 9,657 8,746 08/25/23
Arnold Jonathan SVP, CCO & Div. Head.. SVP, CCO & Div. Head BioP Del. Aug 23 Sell 44.87 87 3,904 57,399 08/25/23
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Aug 23 Sell 44.56 276 12,299 22,040 08/25/23
Hawkeswood Thomas W Pres. Pharma Prod De.. Pres. Pharma Prod Delivery Div Aug 23 Sell 44.72 147 6,574 7,533 08/25/23
Lickfold Charles SVP, CIO SVP, CIO Aug 23 Sell 44.72 190 8,497 11,339 08/25/23
Hunt Patricia Pres. Consumer Healt.. Pres. Consumer Health Div Aug 23 Sell 44.77 106 4,746 11,289 08/25/23
Pravda Ricardo Chief Transformation.. Chief Transformation Officer Aug 23 Sell 44.47 379 16,854 30,224 08/25/23
Pravda Ricardo Chief Transformation.. Chief Transformation Officer Aug 01 Sell 47.14 269 12,681 19,739 08/03/23
Maselli Alessandro President & CEO President & CEO Aug 01 Sell 47.23 1,485 70,137 86,101 08/03/23
Lickfold Charles SVP, CIO SVP, CIO Aug 01 Sell 47.9 135 6,466 5,570 08/03/23
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Aug 01 Sell 47.24 1,637 77,332 60,216 08/03/23
Boerman Manja Pres. BioModalities.. Pres. BioModalities Division May 01 Sell 49.86 1,446 72,098 14,414 05/03/23
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Jan 23 Sell 49.36 643 31,738 16,452 01/25/23
Boerman Manja Pres. BioModalities.. Pres. BioModalities Division Dec 05 Sell 51.70 780 40,326 15,860 12/07/22
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Oct 31 Sell 65.83 2,451 161,349 17,792 11/02/22
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Aug 31 Sell 89.59 2,216 198,531 17,095 09/02/22
Riley Michael A. Pres. Bio Product De.. Pres. Bio Product Delivery Div Aug 26 Sell 104.07 2,491 259,238 6,592 08/30/22
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Aug 26 Sell 104.07 1,639 170,571 23,988 08/30/22
Schmidt Kay A SVP, Enterprise Func.. SVP, Enterprise Functions Aug 24 Sell 103.04 1,321 136,116 17,388 08/26/22
Riley Michael A. Pres. Bio Product De.. Pres. Bio Product Delivery Div Aug 24 Sell 103.04 1,482 152,705 9,083 08/26/22
Pravda Ricardo SVP & Chief HR Offic.. SVP & Chief HR Officer Aug 24 Sell 103.04 1,747 180,011 20,008 08/26/22
Maselli Alessandro President & CEO President & CEO Aug 24 Sell 103.04 4,646 478,724 41,190 08/26/22
Hunt Patricia Pres. Consumer Healt.. Pres. Consumer Health Div Aug 24 Sell 103.04 339 34,931 9,315 08/26/22
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Aug 24 Sell 103.04 1,517 156,312 19,311 08/26/22
Hawkeswood Thomas W Pres. Pharma Prod De.. Pres. Pharma Prod Delivery Div Aug 24 Sell 103.04 671 69,140 6,294 08/26/22
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Aug 24 Sell 103.04 1,840 189,594 25,627 08/26/22
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Aug 24 Sell 103.04 1,670 172,077 20,243 08/26/22
Gennadios Aristippos Group Pres. Pharma &.. Group Pres. Pharma & Consumer Aug 24 Sell 103.04 1,645 169,501 86,769 08/26/22
Gargiulo Mario SVP Global Ops Biolo.. SVP Global Ops Biologics Aug 24 Sell 103.04 1,586 163,421 6,354 08/26/22
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Aug 24 Sell 103.04 4,811 495,725 61,853 08/26/22
Chiminski John R Executive Chair Executive Chair Aug 24 Sell 103.04 38,934 4,011,759 229,888 08/26/22
Castellano Thomas P SVP, Chief Financial.. SVP, Chief Financial Officer Aug 24 Sell 103.04 1,414 145,699 20,099 08/26/22
Carletti Lorenzo SVP Global Ops Ph &.. SVP Global Ops Ph & Cons Hlth Aug 24 Sell 103.04 1,033 106,440 4,985 08/26/22
Boerman Manja Pres. BioModalities.. Pres. BioModalities Division Aug 24 Sell 103.04 3,296 339,620 16,640 08/26/22
Arnold Jonathan SVP & Chief Commerci.. SVP & Chief Commercial Ofcr Aug 24 Sell 103.04 384 39,567 55,958 08/26/22
Schmidt Kay A SVP, Enterprise Func.. SVP, Enterprise Functions Jul 26 Sell 106.9 323 34,529 13,455 07/28/22
Pravda Ricardo SVP & Chief HR Offic.. SVP & Chief HR Officer Jul 26 Sell 106.9 427 45,646 15,337 07/28/22
Maselli Alessandro President & CEO President & CEO Jul 26 Sell 106.9 816 87,230 25,083 07/28/22
Hopson Ricky Pres, Clinical Dev &.. Pres, Clinical Dev & Supply Jul 26 Sell 107.29 903 96,883 17,095 07/28/22
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Jul 26 Sell 107.29 844 90,553 22,350 07/28/22
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Jul 26 Sell 107.29 797 85,510 17,023 07/28/22
Gennadios Aristippos Group Pres. Pharma &.. Group Pres. Pharma & Consumer Jul 26 Sell 106.9 403 43,081 79,784 07/28/22
Gargiulo Mario SVP Global Ops Biolo.. SVP Global Ops Biologics Jul 26 Sell 106.9 969 103,586 3,671 07/28/22
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Jul 26 Sell 106.9 2,546 272,167 53,721 07/28/22